Product category:
Chemical analysis equipment
News Release from: Procognia
Edited by the Laboratorytalk Editorial
Team on 20 November 2006
Awarded 2005 F+S award for protein
arrays
In September 2005, Procognia was awarded the 2005 Frost and Sullivan Competitive Strategy Leadership Award for its expanding portfolio of protein array based technologies
Procognia is helping to develop a fuller understanding of proteins as targets and as therapeutics and is currently working on a programme to array the human proteome in druggable classes Utilising technologies based around protein arrays, Procognia provides both the means for unravelling disease mechanisms and the discovery and development of drugs to treat those diseases
This article was originally published on Laboratorytalk on 23 Jan 2002 at 8.00am (UK)
Related stories
Functional proteins for cancer research
Sense Proteomic has announced that Expressarray p53, its first functional protein array product to aid in cancer research, is now available to researchers
First commercial array of functional proteins
Collection of functional potassium channel regulatory proteins, immobilised in microtitre plate format, is said to be the first functional protein array to be made commercially available
Frost and Sullivan believes that Procognia has achieved outstanding and unparalleled success with these enabling protein array technologies and that the company is setting unprecedented trends for drug discovery research.
Procognia's success is based on its expertise in protein arrays that translates into its core technologies for drug screening and glycosylation analysis.
Procognia's protein arrays for drug screening are available either as catalogue themed arrays of functional human proteins exclusively via Sigma Aldrich, or directly from Procognia on a custom design basis.
Further reading
Agreement targets field of protein glycoanalysis
The combination of Qiagen's Qproteome products with Procognia's on-chip glycoanalysis technology creates guided fractionation solutions
First drug screening human kinase protein array
Procognia announced the introduction of the first human kinase protein function array for use in compound profiling and other drug screening applications in September 2005
Whatever the customer requirement, Procognia's proprietary tag technology ensures their protein function arrays increase their productivity by delivering fast and reproducible results.
Correct glycosylation is critical in the development of protein-based biopharmaceuticals and monitoring early in process development can increase the likelihood of the success of a drug in subsequent clinical trials.
Procognia's custom U-c Fingerprint technology removes the need for sample preparation and gives quantitative data in less than four hours, enabling near real-time glycosylation monitoring.
Researchers wishing to look at glycosylation patterns in a wide range of proteins will have access to this technology via a kit-based product supplied exclusively under license by Qiagen.
Frost and Sullivan analyst Charanya Ramachandran said: "One of biggest factors contributing to our decision to give Procognia this award was our recognition that several leading life science suppliers - namely Sigma-Aldrich, Qiagen and Perkin Elmer - had endorsed the value of this company's technologies by committing to marketing agreements and partnerships.
"Scientists in life science research, drug discovery and the industrial biopharmaceutical industry stand to benefit now that these products are commercially available".
Ron Long (CEO), Chris Lyddon (CFO) and Rachel Fallon (VP R+D and operations) were present to receive Procognia's award at the award banquet on 21 September 2005.
• Procognia: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
